Search Results - "Laura G. Estévez"

Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer by ESTEVEZ, Laura G, GRADISHAR, William J

“…Neoadjuvant chemotherapy (NC) is standard therapy for patients with locally advanced breast cancer and is increasingly used for early-stage operable disease…”
Get full text

An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer by Barnadas, Agustí, Estévez, Laura G., Lluch-Hernández, Ana, Rodriguez-Lescure, Álvaro, Rodriguez-Sanchez, César, Sanchez-Rovira, Pedro

“…Third-generation aromatase inhibitors (AIs) have proven to be superior to tamoxifen in terms of time to disease progression in patients with hormone receptor…”
Get full text

Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial by Bardia, Aditya, Parton, Marina, Kümmel, Sherko, Estévez, Laura G, Huang, Chiun-Sheng, Cortés, Javier, Ruiz-Borrego, Manuel, Telli, Melinda L, Martin-Martorell, Paloma, López, Rafael, Beck, J Thaddeus, Ismail-Khan, Roohi, Chen, Shin-Cheh, Hurvitz, Sara A, Mayer, Ingrid A, Carreon, Daniel, Cameron, Scott, Liao, Serena, Baselga, José, Kim, Sung-Bae

“…There are currently no targeted therapies approved for triple-negative breast cancer (TNBC). A tumor necrosis factor α ( TNFα)-based gene expression signature…”
Get full text

An analysis of the association between breast density and body mass index with breast cancer molecular subtypes in early breast cancer: data from a Spanish population by Calvo, Isabel, González-Rodríguez, Marta, Neria, Fernando, Gallegos, Isabel, García-Sánchez, Lourdes, Sánchez-Gómez, Rosa, Pérez, Silvia, Arenas, María Fernanda, Estévez, Laura G.

“…Purpose Breast cancer is an important health problem, like obesity and dyslipidemia, with a strong association between body mass index (BMI) and breast cancer…”
Get full text

Optofluidic device for the quantification of circulating tumor cells in breast cancer by Pedrol, Eric, Garcia-Algar, Manuel, Massons, Jaume, Nazarenus, Moritz, Guerrini, Luca, Martínez, Javier, Rodenas, Airan, Fernandez-Carrascal, Ana, Aguiló, Magdalena, Estevez, Laura G., Calvo, Isabel, Olano-Daza, Ana, Garcia-Rico, Eduardo, Díaz, Francesc, Alvarez-Puebla, Ramon A.

“…Metastatic cancer patients require a continuous monitoring during the sequential treatment cycles to carefully evaluate their disease evolution. Repetition of…”
Get full text

Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ by Estévez, Laura G, Suarez-Gauthier, Ana, García, Elena, Miró, Cristina, Calvo, Isabel, Fernández-Abad, María, Herrero, Mercedes, Marcos, Manuel, Márquez, Cristina, Lopez Ríos, Fernando, Perea, Sofía, Hidalgo, Manuel

“…Human epidermal growth factor receptor 2 (HER2) amplification is frequent in ductal carcinoma in situ (DCIS) of the breast and is associated with poorly…”
Get full text

Current perspectives of treatment of ductal carcinoma in situ by Estévez, Laura G, Álvarez, Isabel, Seguí, Miguel Ángel, Muñoz, Monserrat, Margelí, Mireia, Miró, Cristina, Rubio, Carmen, Lluch, Ana, Tusquets, Ignasi

“…Summary DCIS is a genetically diverse group of diseases with different prognosis. The similarities between DCIS and ductal infiltrating carcinoma (DIC) suggest…”
Get full text

Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer by Muñoz, Montserrat, Estévez, Laura G, Alvarez, Isabel, Fernández, Yolanda, Margelí, Mireia, Tusquets, Ignasi, Seguí, Miguel Ángel, Lluch, Ana

“…Summary The clinical decision to treat early-stage breast cancer with adjuvant chemotherapy is sometimes a difficult one because 70–80% of patients who receive…”
Get full text

Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: Efficacy and correlation with biological markers in a phase II, multicenter study by ESTEVEZ, Laura G, CUEVAS, José Miguel, ANTON, Antonio, FLORIAN, Jesus, LOPEZ-VEGA, José Manuel, VELASCO, Amalia, LOBO, Francisco, HERRERO, Ana, FORTES, José

“…This is one of the first reports of weekly docetaxel (Taxotere) in the neoadjuvant treatment of stage II and III breast cancer. We evaluated docetaxel's…”
Get full text

A Phase II Study of Capecitabine and Vinorelbine in Patients with Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes by Estévez, Laura G, Batista, Norberto, Sánchez-Rovira, Pedro, Velasco, Amalia, Provencio, Mariano, León, Ana, Dómine, Manuel, Cruz, Josefina, Rodríguez, Milva

“…Abstract Purpose The aim of this study was to evaluate the efficacy and safety of capecitabine in combination with vinorelbine in patients with metastatic…”
Get full text

Evidence-based use of taxanes in the adjuvant setting of breast cancer. A review of randomized phase III trials by Estévez, Laura G, Muñoz, Montserrat, Alvarez, Isabel, Fernández, Yolanda, García-Mata, Jesús, Ruiz-Borrego, Manuel, Tusquets, Ignasi, Seguí, Miguel Ángel, Rodríguez-Lescure, Alvaro, Adrover, Encarna, Lluch, Ana

“…Summary Six major randomized clinical trials evaluating the role of taxanes in the adjuvant setting of breast cancer have demonstrated significant improvements…”
Get full text

Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients: Preliminary results of a phase II and pharmacogenomic study by Estévez, Laura G, Sánchez-Rovira, Pedro, Dómine, Manuel, León, A, Calvo, Isabel, Jaén, Ana, Casado, Victoria, Rubio, Gustavo, Dı́az, Mariano, Miró, Cristina, Lobo, Francisco

“…The purpose of this study is to evaluate the efficacy and safety of a biweekly neoadjuvant docetaxel/gemcitabine regimen in patients with histologically…”
Get full text

The Use of Taxanes in the Neoadjuvant Treatment of Breast Cancer: A Review of Randomized Phase II/III Trials by Tusquets, Ignasi, Estévez, Laura G, Alvarez, Isabel, Muñoz, Montserrat, Adrover, Encarna, Albanell, Joan, Rodríguez, César, Ángel Seguí, Miguel, Rodríguez-Lescure, Alvaro, Ruiz-Borrego, Manuel, García-Mata, Jesús, Lluch, Ana

“…Abstract This review examines all randomized studies that evaluated the role of taxanes in the neoadjuvant treatment of breast cancer and have reported results…”
Get full text

Abstract P4-03-39: Breast density and Body Mass Index association with breast cancer molecular subtypes in early breast cancer Spanish population by Calvo, Isabel, González, Marta, Neria, Fernando, Gallegos, Isabel, García-Sánchez, Lourdes, Pérez, Silvia, Estévez, Laura G.

“…Obesity is a major health problem and is closely related to the incidence and progression of breast cancer (BC). Likewise, mammogram breast density (MBD) is a…”
Get full text

Neoadjuvant endocrine therapy for breast cancer: past, present and future by Barnadas, Agustí, Gil, Miguel, Sánchez-Rovira, Pedro, Llombart, Antonio, Adrover, Encarna, Estevez, Laura G, de la Haba, Juan, Calvo, Lourdes

“…Combined treatments together with surgery, radiotherapy, chemotherapy, and endocrine therapy have contributed substantially to the improved survival rate in…”
Get full text

Advanced breast cancer: chemotherapy phase III trials that change a standard by Estevez, Laura G, Tusquets, Ignasi, Muñoz, Montse, Adrover, Encarnación, Rovira, Pedro Sánchez, Seguí, Miguel Ángel, Rodríguez, César A, Lescure, Álvaro Rodríguez, Ruiz, Manuel, Álvarez, Isabel, Mata, Jesús García

“…At the present time, there is not a standard regimen in upfront metastatic setting for breast cancer. A wide variety of regimens which includes anthracyclines,…”
Get full text

Neoadjuvant chemotherapy in breast cancer by Estévez, Laura G.

Get full text

Gemcitabine and carboplatin for patients with advanced non-small cell lung cancer by Dómine, M, Casado, V, Estévez, L G, León, A, Martin, J I, Castillo, M, Rubio, G, Lobo, F

“…The survival of patients with advanced non-small cell lung cancer remains poor. Cisplatin-based chemotherapy produces a modest benefit in survival compared…”
Get more information

Analysis of inactivation of PI3K/AKT/mTOR signaling pathway using neoadjuvant BKM120 in PI3KCA mutated early breast cancer by Laura, Estevez G, Ana, Suarez, Isabel, Calvo, Fernandez Abad, Maria, Perea, Sofia, Hidalgo, Manuel

“…Abstract only…”
Get full text

Can Onco type DX Recurrence Score (RS) be used in Luminal A and Luminal B breast cancer patients (pts) to predict the likely benefit of chemotherapy? A retrospective unicentric study in Spanish population by Estevez, Laura G., Calvo, Isabel, Fernandez-Abad, Maria, Cruz, Juan Jose, Suarez, Ana, Lopez-Rios, Fernando, Hidalgo, Manuel

“…Abstract only 40 Background: The 2011 St Gallen guidelines recommend the use of Ki67 as a surrogate marker for luminal A and Luminal B breast cancer subtypes…”
Get full text